Drug Trial Radar · NCT01774721
ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.
Last checked: Nov 20, 2026Latest source record: Nov 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
452
Actual
Start
May 9, 2013
Primary completion
Jul 29, 2016
Study completion Jan 27, 2022
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jan 24, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multinational, multicenter, randomized, open-label, Phase 3 study comparing the efficacy and safety of treatment with dacomitinib (PF-00299804) to treatment with gefitinib in patients with locally advanced or metastatic non-small cell lung cancer, with epidermal growth factor receptor EGFR-activating mutation (s). Analyses of primary objective (Progression Free Survival) will be done as defined in the protocol.
Conditions
- Non-small Cell Lung Cancer With EGFR-Activating Mutations
Interventions
Dacomitinib (PF-00299804)Drug
Dacomitinib (PF-00299804) 45 mg tablets, continuous oral daily dosing.
GefitinibDrug
Gefitinib 250 mg tablets, continuous oral daily dosing.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) ReviewTime frame: Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)
Locations
52 sites in 7 countries. Site status is shown where the registry gives one.
Site not named
Beijing, China
Site not named
Changchun, China
Site not named
Changsha, China
Site not named
Chengdu, China
Site not named
Chongqing, China
Site not named
Fuzhou, China
Site not named
Guangzhou, China
Site not named
Hangzhou, China
Site not named
Hefei, China
Site not named
Nanning, China
Site not named
Shanghai, China
Site not named
Shenyang, China
Site not named
Tianjin, China
Site not named
Wuhan, China
Site not named
Wuxi, China
Site not named
Hong Kong, Hong Kong
Site not named
Shatin, Hong Kong
Site not named
Catania, Italy
Site not named
Lecco, Italy
Site not named
Livorno, Italy
Site not named
Meldola, Italy
Site not named
Milan, Italy
Site not named
Naples, Italy
Site not named
Perugia, Italy
Site not named
Ravenna, Italy
Site not named
Roma, Italy
Site not named
Trento, Italy
Site not named
Viterbo, Italy
Site not named
Hokkaido, Asahikawa, Japan
Site not named
Kashiwa, Chiba, Japan
Site not named
Matsuyama, Ehime, Japan
Site not named
Yokohama, Kanagawa, Japan
Site not named
Tokyo, Koto-ku, Japan
Site not named
Sakai, Osaka, Japan
Site not named
Sayama, Osaka, Japan
Site not named
Sunto-gun, Shizouka, Japan
Site not named
Chuo-Ku, Tokyo, Japan
Site not named
Gdansk, Poland
Site not named
Olsztyn, Poland
Site not named
Poznan, Poland
Showing 40 of 52 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.